CEL-SCI presents solid science as detractors keep changing the subject

BioMedReports.Com, the news portal which covers Wall Street's biomedical, has issued a special editorial report about CEL-SCI Corp's presentation of data about the company's dendritic H1N1, being developed as a treatment for H1N1 hospitalized patients.

The company has attracted a great deal of interest from the biomedical investment community and while some Wall Street reporters have painted the company as little more than the latest "flu stock" play, the fact remains that both the FDA and the medical research community has taken notice of the promising new technology platform.

As indicated in the new editorial report by biotech investment writer, Vinny Cassano, the data presented by Ken Rosenthal, Professor, Microbiology, Immunology and Biochemistry, Northeastern Ohio Universities Colleges of Medicine and Pharmacology is the only set of facts sanctioned by the company.

"There appears to be a bad-natured effort to keep negative headlines alive and to draw attention away from the facts and reports that have investors trading the stock at volume levels that haven't been seen by the company for years," writes Mr Cassano.

The complete special report is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/12057-the-latest-on-cel-sci-cvm.html